HK1166604A1 - Combination of avermectins or mylbemycins with adrenergic receptors for treating or preventing skin diseases - Google Patents

Combination of avermectins or mylbemycins with adrenergic receptors for treating or preventing skin diseases

Info

Publication number
HK1166604A1
HK1166604A1 HK12107254.2A HK12107254A HK1166604A1 HK 1166604 A1 HK1166604 A1 HK 1166604A1 HK 12107254 A HK12107254 A HK 12107254A HK 1166604 A1 HK1166604 A1 HK 1166604A1
Authority
HK
Hong Kong
Prior art keywords
mylbemycins
avermectins
treating
combination
skin diseases
Prior art date
Application number
HK12107254.2A
Other languages
English (en)
Chinese (zh)
Inventor
Andr Jomard
Laurent Fredon
Olivier Roye
Original Assignee
Galderma Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Res & Dev filed Critical Galderma Res & Dev
Publication of HK1166604A1 publication Critical patent/HK1166604A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HK12107254.2A 2009-02-16 2012-07-24 Combination of avermectins or mylbemycins with adrenergic receptors for treating or preventing skin diseases HK1166604A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0950981A FR2942138A1 (fr) 2009-02-16 2009-02-16 Association de composes pour le traitement ou la prevention des affections dermatologiques
PCT/FR2010/050259 WO2010092312A1 (fr) 2009-02-16 2010-02-16 Association d' avermectines ou mylbemycines avec des récepteurs adrénergiques pour le traitement ou la prévention des affections dermatologiques

Publications (1)

Publication Number Publication Date
HK1166604A1 true HK1166604A1 (en) 2012-11-02

Family

ID=41056814

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12107254.2A HK1166604A1 (en) 2009-02-16 2012-07-24 Combination of avermectins or mylbemycins with adrenergic receptors for treating or preventing skin diseases

Country Status (14)

Country Link
US (2) US8669233B2 (xx)
EP (1) EP2395998B1 (xx)
JP (1) JP5538434B2 (xx)
KR (1) KR101365011B1 (xx)
CN (1) CN102395365B (xx)
AU (1) AU2010212634B2 (xx)
BR (1) BRPI1005931A8 (xx)
CA (1) CA2751543C (xx)
ES (1) ES2545395T3 (xx)
FR (1) FR2942138A1 (xx)
HK (1) HK1166604A1 (xx)
MX (1) MX2011008391A (xx)
RU (1) RU2531087C2 (xx)
WO (1) WO2010092312A1 (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7812049B2 (en) * 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
HUE036436T2 (hu) * 2009-06-30 2018-07-30 Burcon Nutrascience Mb Corp Savoldható szójafehérje-izolátumok ("S800") elõállítás
US20120082625A1 (en) * 2010-09-28 2012-04-05 Michael Graeber Combination treatment for rosacea
WO2013016072A1 (en) 2011-07-22 2013-01-31 Allergan, Inc. Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
UA109359C2 (xx) 2011-11-10 2015-08-10 Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
FR3000395A1 (fr) * 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et d'oxymetazoline pour le traitement de la rosacee
US9233118B2 (en) * 2013-07-08 2016-01-12 Galderma S.A. Treatment of papulopustular rosacea with ivermectin
US9782425B2 (en) 2013-07-08 2017-10-10 Galderma S.A. Treatment of papulopustular rosacea with ivermectin
KR101948779B1 (ko) 2013-10-07 2019-05-21 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치 및 이의 사용 방법
JP6310070B2 (ja) 2013-10-07 2018-04-11 テイコク ファーマ ユーエスエー インコーポレーテッド デクスメデトミジン経皮組成物を用いる、注意欠陥多動性障害、不安症及び不眠症の治療法及び組成物
US10987342B2 (en) 2013-10-07 2021-04-27 Teikoku Pharma Usa, Inc. Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine
JP6448641B2 (ja) * 2013-11-29 2019-01-09 ガルデルマ・ソシエテ・アノニム アトピー性皮膚炎の治療及び／又は予防のためのアベルメクチンファミリー又はミルベマイシンファミリーの化合物
WO2016096795A1 (en) * 2014-12-15 2016-06-23 Galderma Sa Compound of the avermectin family for treating and/or preventing inflammatory dermatoses
WO2017085226A1 (en) * 2015-11-17 2017-05-26 Galderma Sa Use of ivermectin and brimonidine in the treatment and/or prevention of moderate to severe rosacea
EP3493795A1 (en) * 2016-08-04 2019-06-12 Nestlé Skin Health SA Compositions and the use thereof for treating or preventing rosacea
RU2645932C1 (ru) * 2017-02-15 2018-02-28 Ольга Юрьевна Олисова Способ комбинированной наружной терапии для больных эритематозно-папулезной розацеа
KR102039608B1 (ko) * 2017-11-03 2019-11-01 주식회사 셀버틱스 미도드린을 포함하는 조성물 및 이의 용도
KR20210113975A (ko) * 2018-10-12 2021-09-17 호비온 사이언티아 리미티드 마크로사이클릭 락톤 제제, 이의 제조방법, 및 안과 기생충에 대한 이차적인 병리를 치료하는데 있어서의 상기 제제의 용도
US20220160668A1 (en) 2020-11-23 2022-05-26 Sight Sciences, Inc. Formulations and methods for treating conditions of the eye

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952372A (en) * 1998-09-17 1999-09-14 Mcdaniel; William Robert Method for treating rosacea using oral or topical ivermectin
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US7812049B2 (en) * 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
FR2883181B1 (fr) 2005-03-17 2007-05-18 Galderma Sa Composition a base d'une avermectine et d'acide azelaique notamment pour le traitement de la rosacee
FR2886851B1 (fr) 2005-06-10 2007-10-05 Galderma Sa Composition a base d'une avermectine et de metronidazole notamment pour le traitement de la rosacee
FR2886852B1 (fr) * 2005-06-10 2007-11-23 Galderma Sa Composition a base d'une avermectine et d'hydrocortisone notamment pour le traitement de la rosacee
FR2886850B1 (fr) * 2005-06-10 2007-10-05 Galderma Sa Composition a base d'une avermectine et de peroxyde de benzoyle notamment pour le traitement de la rosacee
FR2891460B1 (fr) * 2005-09-30 2010-07-30 Galderma Sa Utilisation d'au moins un compose de la famille des avermectines pour le traitement des pathologies ophtalmiques dues au demodex folliculorum.
AU2006313447A1 (en) * 2005-09-30 2007-05-18 Galderma S.A. Use of at least one avermectin or milbemycin in the treatment of ophthalmic pathologies
TWI435729B (zh) * 2005-11-09 2014-05-01 Combinatorx Inc 治療病症之方法，組合物及套組
FR2901703B1 (fr) * 2006-05-31 2012-12-07 Galderma Res & Dev Utilisation de zatosetron pour le traitement de la rosacee, et compositions pharmaceutiques
FR2906466B1 (fr) * 2006-09-28 2008-11-28 Galderma Sa Utilisation de composes de la famille des milbemycines pour le traitement de desordres dermatologiques chez l'homme
FR2906470B1 (fr) * 2006-09-28 2012-09-21 Galderma Sa Utilisation de la 6'-ethyl-lepimectine, la 6'-methyl-lepimectine ou leurs derives pour le traitement de desordres dermatologiques chez l'homme

Also Published As

Publication number Publication date
RU2531087C2 (ru) 2014-10-20
AU2010212634B2 (en) 2015-09-10
US8669233B2 (en) 2014-03-11
JP2012517989A (ja) 2012-08-09
BRPI1005931A8 (pt) 2017-12-26
CA2751543C (fr) 2015-06-16
US20140249096A1 (en) 2014-09-04
WO2010092312A1 (fr) 2010-08-19
KR101365011B1 (ko) 2014-02-19
JP5538434B2 (ja) 2014-07-02
ES2545395T3 (es) 2015-09-10
MX2011008391A (es) 2011-09-01
CA2751543A1 (fr) 2010-08-19
FR2942138A1 (fr) 2010-08-20
BRPI1005931A2 (pt) 2017-05-30
CN102395365B (zh) 2014-06-25
US20120035123A1 (en) 2012-02-09
RU2011138021A (ru) 2013-03-27
KR20110116059A (ko) 2011-10-24
EP2395998B1 (fr) 2015-07-08
AU2010212634A1 (en) 2011-09-08
EP2395998A1 (fr) 2011-12-21
CN102395365A (zh) 2012-03-28

Similar Documents

Publication Publication Date Title
HK1166604A1 (en) Combination of avermectins or mylbemycins with adrenergic receptors for treating or preventing skin diseases
EP2432476A4 (en) METHOD FOR THE TREATMENT OR PREVENTION OF EYE DISEASES
IL212793A0 (en) Handpiece for treating skin
HK1217763A1 (zh) 用於治療疾病的方法
PL2643004T3 (pl) Kompozycja oligosacharydów do leczenia chorób skóry
HK1171168A1 (zh) 利用拉喹莫德治療克羅恩病
EP2303184A4 (en) GLAUCOMA ASSOCIATION TREATMENT
EP2282795A4 (en) TREATMENT OF RESPIRATORY DISEASES
ZA201203289B (en) Use of bethanechol for treatment of zerostomia
EP2654745A4 (en) COMPOSITION FOR TREATING SKIN CONDITIONS OF THE SKIN
PL2647337T3 (pl) Urządzenie wywołujące bodźce skóry
HK1145961A1 (en) Skin patch laminate body
GB0915515D0 (en) Treatment of vasculoproliferative conditions
ZA201304868B (en) Treatment of pain associated with dislocation of basal endometrium
ZA201209323B (en) Methods of treating or preventing estrogen-related diseases
GB0902040D0 (en) Composition for treatment of skin
IL214133A0 (en) Skin treatment
EP2436683A4 (en) AGENT FOR TREATING OR PREVENTING DISEASES ASSOCIATED WITH THE ACTIVITY OF NEUROTROPHIC AGENTS
PL2435026T3 (pl) Leczenie zrostu tkanek
ZA201202379B (en) Antagonists of dsgs2 for treatment of cancer
PL2456445T3 (pl) Środek do leczenia chorób skóry
GB201010638D0 (en) Composition for treatment of skin
ZA201005770B (en) The treatment of damaged skin
GB2473735B (en) Skin treatment formulation
GB0908666D0 (en) Treatment of proteostatic disease

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190211